{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/69810d312c62bf72e54d82a7/6ad79fdea25058b22af5321d?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Ep. 34: IBM Watson's $62 Million Lesson for Healthcare AI ","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/69810d312c62bf72e54d82a7/1792516033349-e8c0c52c-f8d6-4fb1-8ae7-2bdd428235d8.jpeg?height=200","description":"<p>Artificial intelligence is transforming healthcare, but how can leaders distinguish promising technology from an innovation that&#39;s actually ready to implement? </p><p><br></p><p>In the early 2010s, IBM Watson and MD Anderson Cancer Center set out to revolutionize cancer care through AI-powered clinical decision support. The vision was compelling, but the initiative was ultimately discontinued after approximately $62 million in project-related spending, without ever being deployed for patient care. </p><p><br></p><p>In Episode 34 of Viral Healthcare, Dr. Bruce Spurlock revisits the IBM Watson story and explores what healthcare leaders can learn from it today. From interoperability challenges and clinical workflows to organizational readiness and the pressure to adopt AI before competitors, Bruce examines why even promising innovations can struggle in real healthcare environments. </p><p><br></p><p>He also explores today&#39;s AI applications, including clinical documentation, diabetic retinal screening, and predictive analytics, and shares five questions leaders should ask before making a major technology investment. </p><p><br></p><p>The question isn&#39;t whether AI has a future in healthcare. It&#39;s whether the AI investment you&#39;re considering is right for your organization today. </p><p><br></p><p>#HealthcareAI #ArtificialIntelligence #HealthcareLeadership #HealthcareInnovation #DigitalHealth </p>","author_name":"Bruce Spurlock"}